High-End Linear Accelerator to Transform Advanced Cancer Care in Delhi Hospitals

New Delhi | Special Correspondent: Arun Sharma

In a major boost to public cancer care in the national capital, doctors at the Delhi State Cancer Institute (DSCI) have partnered with Indian Oil Corporation Limited (IOCL) for the installation of a high-energy Linear Accelerator—one of the most advanced radiation therapy systems used for precise and effective cancer treatment. The project is being supported under IOCL’s Corporate Social Responsibility (CSR) initiative.


The Memorandum of Understanding (MoU) was signed on January 21, 2026, at the Delhi Secretariat in the presence of senior health officials, leading oncologists, and representatives from IOCL and allied agencies. The collaboration marks a significant step towards equipping state-run hospitals with modern, life-saving oncology infrastructure.


The MoU signing was witnessed by Mr Yash Chaudhary, Special Secretary (Health & Family Welfare), along with Dr Ravinder Singh, Joint Director, DSCI, and Dr Pragya Shukla, Head of the Department of Clinical Oncology, DSCI. IOCL was represented by Mr Bibhuti Ranjan Pradhan, Executive Director (Coordination & CSR), and Mr Nitin Vashist, Deputy General Manager (CSR). Officials from HLL Infra Tech Services Limited (HITES), including Mr Vineet Agarwal, Manager, and Mr Noor Alam, Senior Assistant, were also present.


Officials said the high-end Linear Accelerator is expected to be delivered by the end of March 2026. After installation, commissioning, and mandatory approvals from the Atomic Energy Regulatory Board (AERB), the machine is likely to become fully operational by the end of the year.


Calling the development a landmark for public healthcare, Dr Vinod Kumar, Director, Delhi State Cancer Institute, said the new facility would significantly enhance treatment outcomes.


“The installation of this high-energy Linear Accelerator marks a major milestone for Delhi State Cancer Institute. This advanced technology will enable our doctors to deliver highly precise, world-class radiation therapy and greatly improve outcomes for cancer patients. We are grateful to IOCL for strengthening public healthcare through its CSR support,” he said.


Medical experts noted that the system will substantially increase DSCI’s capacity to provide accurate, patient-centric cancer treatment, benefiting thousands of patients every year, particularly those from economically weaker sections.


Emphasising the social impact, Dr Pragya Shukla, Head of Clinical Oncology, said the initiative would directly benefit the poorest cancer patients.


“This project has been made possible with strong government support, and we are committed to utilising this technology to its fullest for delivering recommended treatment to the most vulnerable sections. IOCL has also assured further assistance once the Linear Accelerator becomes functional,” she said.


Dr Ravinder Singh, Joint Director, DSCI, underlined the importance of public–corporate partnerships in healthcare delivery.


“DSCI sincerely acknowledges IOCL’s commitment to social responsibility and healthcare development. The addition of this high-end Linear Accelerator will reduce patient waiting times and enhance our ability to deliver safe, efficient, and evidence-based radiotherapy. Such collaborations are crucial for improving cancer care outcomes in the country,” he said.


Health officials said the project reflects the government’s broader vision of upgrading public hospitals with advanced medical technology, ensuring equitable access to quality cancer treatment and reinforcing Delhi’s position as a growing hub for modern cancer care.